SYBX
Synlogic, Inc. NASDAQ Listed Sep 30, 2015$0.60
Mkt Cap $7.0M
52w Low $0.54
4.2% of range
52w High $1.96
50d MA $0.63
200d MA $1.16
P/E (TTM)
-7.6x
EV/EBITDA
0.2x
P/B
0.6x
Debt/Equity
0.0x
ROE
-8.5%
P/FCF
-3.2x
RSI (14)
—
ATR (14)
—
Beta
0.49
50d MA
$0.63
200d MA
$1.16
Avg Volume
12.1K
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
301 Binney Street · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.09 | 0.12 | +233.3% | 0.60 | +1.7% | +1.7% | -1.6% | +11.7% | -1.9% | +8.8% | — |
| Nov 13, 2025 | AMC | -0.11 | -0.19 | -72.7% | 1.67 | +0.6% | +0.6% | +0.6% | -2.4% | -1.8% | -1.2% | — |
| Aug 7, 2025 | AMC | -0.13 | -0.04 | +69.2% | 1.36 | -2.2% | +2.9% | -1.4% | +5.8% | +2.7% | -3.3% | — |
| Mar 6, 2025 | AMC | -0.10 | -0.06 | +40.0% | 1.31 | +4.6% | +0.8% | -4.5% | -2.4% | +0.8% | -3.2% | — |
| Nov 12, 2024 | AMC | -0.18 | -0.01 | +94.4% | 1.46 | -3.4% | -3.4% | -1.4% | -2.2% | +0.7% | -0.7% | — |
| Aug 8, 2024 | AMC | -0.51 | 0.16 | +131.4% | 1.57 | +4.5% | -7.0% | -4.1% | -2.1% | +2.9% | +0.7% | — |
| May 14, 2024 | AMC | -0.80 | -2.60 | -225.0% | 1.75 | +0.0% | -1.7% | -2.3% | -1.8% | -1.8% | +1.9% | — |
| Mar 19, 2024 | AMC | -1.11 | -1.71 | -54.1% | 1.78 | +0.0% | -2.8% | +1.2% | +2.9% | +0.0% | -1.1% | — |
| Nov 9, 2023 | AMC | -2.55 | -2.57 | -0.8% | 1.81 | -0.6% | +2.2% | -2.7% | +17.8% | -0.9% | -5.2% | — |
| Aug 10, 2023 | AMC | -3.90 | -3.15 | +19.2% | 7.47 | +0.0% | +2.4% | +0.1% | +4.0% | -1.0% | -4.3% | — |
| May 11, 2023 | AMC | -3.75 | -3.45 | +8.0% | 8.37 | +0.2% | -0.4% | -1.1% | -1.9% | +4.6% | +1.4% | — |
| Mar 29, 2023 | AMC | -3.90 | -3.60 | +7.7% | 9.45 | -3.1% | +6.3% | -5.7% | -8.2% | -7.6% | -6.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20 | HC Wainwright & Co. | Upgrade | Sell → Neutral | — | $1.78 | $1.78 | +0.0% | -2.8% | +1.2% | +2.9% | +0.0% | -1.1% |
| Feb 9 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $3.45 | $1.61 | -53.3% | -48.7% | -2.8% | +1.2% | +2.3% | +3.4% |
| Feb 9 | HC Wainwright & Co. | Downgrade | Buy → Sell | — | $3.45 | $1.61 | -53.3% | -48.7% | -2.8% | +1.2% | +2.3% | +3.4% |
| Feb 9 | Chardan Capital | Downgrade | Buy → Neutral | — | $3.45 | $1.61 | -53.3% | -48.7% | -2.8% | +1.2% | +2.3% | +3.4% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $7.47 | $7.47 | +0.0% | +2.4% | +0.1% | +4.0% | -1.0% | -4.3% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.47 | $7.47 | +0.0% | +2.4% | +0.1% | +4.0% | -1.0% | -4.3% |
| Aug 10 | Chardan Capital | Maintains | Buy → Buy | — | $7.35 | $7.39 | +0.5% | +1.6% | +2.4% | +0.1% | +4.0% | -1.0% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.35 | $7.39 | +0.5% | +1.6% | +2.4% | +0.1% | +4.0% | -1.0% |
| Jul 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.53 | $7.92 | +5.2% | +5.6% | -6.4% | +3.0% | -1.4% | -0.7% |
| Jul 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.84 | $7.83 | -0.1% | -4.0% | +5.6% | -6.4% | +3.0% | -1.4% |
| Jun 6 | Chardan Capital | Maintains | Buy → Buy | — | $7.30 | $7.99 | +9.5% | +28.5% | -8.8% | +4.1% | -0.2% | -3.7% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.30 | $7.99 | +9.5% | +28.5% | -8.8% | +4.1% | -0.2% | -3.7% |
| Jun 5 | Chardan Capital | Maintains | Buy → Buy | — | $8.55 | $8.40 | -1.8% | -14.6% | +28.5% | -8.8% | +4.1% | -0.2% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.55 | $8.40 | -1.8% | -14.6% | +28.5% | -8.8% | +4.1% | -0.2% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.58 | $8.70 | +1.4% | -0.6% | -1.2% | -0.4% | +1.8% | -4.3% |
| May 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.46 | $8.25 | -2.5% | +1.4% | -0.6% | -1.2% | -0.4% | +1.8% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.34 | $8.85 | +6.1% | -1.1% | -1.9% | +4.6% | +1.4% | -0.6% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 30 | Chardan Capital | Maintains | Buy → Buy | — | $9.45 | $9.16 | -3.1% | +6.3% | -5.7% | -8.2% | -7.6% | -6.6% |
| Mar 29 | Chardan Capital | Maintains | Buy → Buy | — | $9.18 | $9.47 | +3.2% | +2.9% | +6.3% | -5.7% | -8.2% | -7.6% |
| Nov 11 | Chardan Capital | Maintains | Buy → Buy | — | $9.65 | $10.45 | +8.3% | +15.0% | -1.4% | +2.7% | -4.6% | -9.4% |
| Nov 10 | Chardan Capital | Maintains | Buy → Buy | — | $10.35 | $11.25 | +8.7% | -6.8% | +15.0% | -1.4% | +2.7% | -4.6% |
| Oct 18 | Oppenheimer | Maintains | Outperform → Outperform | — | $16.20 | $16.50 | +1.9% | +0.0% | +0.9% | -1.8% | -0.9% | -10.4% |
| Oct 17 | Oppenheimer | Maintains | Outperform → Outperform | — | $15.75 | $16.35 | +3.8% | +2.9% | +0.0% | +0.9% | -1.8% | -0.9% |
| May 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $16.05 | $16.35 | +1.9% | +8.4% | -6.0% | +6.4% | -5.2% | +10.0% |
| May 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $18.75 | $19.20 | +2.4% | -14.4% | +8.4% | -6.0% | +6.4% | -5.2% |
| Mar 18 | SVB Leerink | Maintains | Outperform → Outperform | — | $30.60 | $30.60 | +0.0% | +9.3% | +0.0% | +9.9% | +0.4% | +2.4% |
| Mar 17 | SVB Leerink | Maintains | Outperform → Outperform | — | $32.10 | $32.10 | +0.0% | -4.7% | +9.3% | +0.0% | +9.9% | +0.4% |
| Nov 24 | Oppenheimer | Upgrade | Perform → Outperform | — | $36.00 | $38.76 | +7.7% | +10.0% | -1.9% | -6.6% | +2.9% | -2.8% |
| Nov 23 | Oppenheimer | Upgrade | Perform → Outperform | — | $37.05 | $37.80 | +2.0% | -2.8% | +10.0% | -1.9% | -6.6% | +2.9% |
| Nov 11 | SVB Leerink | Maintains | Outperform → Outperform | — | $39.90 | $39.45 | -1.1% | -0.4% | +4.2% | +0.0% | -0.4% | -2.5% |
| Nov 10 | SVB Leerink | Maintains | Outperform → Outperform | — | $40.35 | $44.10 | +9.3% | -1.1% | -0.4% | +4.2% | +0.0% | -0.4% |
| Oct 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.25 | $41.70 | +1.1% | +0.0% | -2.2% | +0.4% | -4.1% | +0.0% |
| Oct 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.95 | $40.80 | -0.4% | +0.7% | +0.0% | -2.2% | +0.4% | -4.1% |
| Sep 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $49.35 | $52.80 | +7.0% | +12.8% | -3.8% | -2.2% | -8.9% | -0.3% |
| Sep 19 | Piper Sandler | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Jun 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $63.00 | $63.90 | +1.4% | -1.4% | -3.1% | -3.0% | +5.4% | -5.1% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 18 | JonesTrading | Maintains | Buy → Buy | — | $62.70 | $67.17 | +7.1% | -3.8% | +11.2% | -2.0% | -5.9% | -5.8% |
| Jan 13 | Chardan Capital | Maintains | Buy → Buy | — | $36.00 | $44.85 | +24.6% | +32.5% | +2.5% | +8.0% | +8.2% | +0.8% |
| Jan 12 | Chardan Capital | Maintains | Buy → Buy | — | $36.15 | $36.45 | +0.8% | -0.4% | +32.5% | +2.5% | +8.0% | +8.2% |
| Aug 21 | Oppenheimer | Downgrade | Outperform → Perform | — | $52.35 | $47.85 | -8.6% | -7.4% | -3.1% | +4.5% | -1.5% | +0.6% |
| Aug 21 | Citigroup | Downgrade | Buy → Sell | — | $52.35 | $47.85 | -8.6% | -7.4% | -3.1% | +4.5% | -1.5% | +0.6% |
| Aug 20 | Oppenheimer | Downgrade | Outperform → Perform | — | $72.45 | $50.55 | -30.2% | -27.7% | -7.4% | -3.1% | +4.5% | -1.5% |
| Aug 20 | Citigroup | Downgrade | Buy → Sell | — | $72.45 | $50.55 | -30.2% | -27.7% | -7.4% | -3.1% | +4.5% | -1.5% |
| Apr 30 | Jefferies | Maintains | Buy → Buy | — | $116.10 | $120.60 | +3.9% | +10.9% | +1.9% | -8.1% | +9.0% | -0.8% |
| Feb 13 | BTIG Research | Maintains | Buy → Buy | — | $143.40 | $144.75 | +0.9% | +7.1% | -12.6% | +3.8% | +0.1% | +2.2% |
| Dec 13 | Chardan Capital | Maintains | Buy → Buy | — | $114.60 | $116.85 | +2.0% | -1.3% | +1.3% | -2.7% | -5.1% | -5.4% |
| Aug 24 | Citigroup | Upgrade | Neutral → Buy | — | $117.90 | $127.50 | +8.1% | +15.1% | +2.4% | +3.1% | +0.3% | +4.4% |
| Aug 23 | Citigroup | Upgrade | Neutral → Buy | — | $118.65 | $118.35 | -0.3% | -0.6% | +15.1% | +2.4% | +3.1% | +0.3% |
No insider trades available.
No recent filings available.
Data updated apr 28, 2026 10:18pm
· Source: massive.com